Global Clinical Chemistry Analyzer Market Overview:
Clinical chemistry analysers are the devices used to determine the concentration of certain metabolites, electrolytes, proteins, and drugs in samples of plasma, urine, serum, cerebrospinal fluid, and/or other body fluids. Significant advancement in healthcare industry and increase in population across globe have boosted the demand for clinical chemistry analyser market. North America held the largest market share of the clinical chemistry analyser due to various government supportive policies & guidelines and high investments in research and testing. Some of the key players profiled in the study are Beckman Coulter (United States), Abbott Diagnostics (United States), Siemens AG (Germany), Roche Diagnostics (Switzerland), Ortho-Clinical Diagnostics (United States), Thermo Fisher Scientific (United States), Randox Laboratories Ltd. (United Kingdom), ElitechGroup (France), Mindray (China) and Horiba (Japan). According to Market Analyst at AMA, the Global Clinical Chemistry Analyzer market may see a growth rate of 5.2%
On the basis of geography, the market of Clinical Chemistry Analyzer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Measurement Technology, the sub-segment i.e. Photometric and Colorimetric Testing will boost the Clinical Chemistry Analyzer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Size, the sub-segment i.e. Small (400-800 Test/H) will boost the Clinical Chemistry Analyzer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising number of chronic diseases such as diabetes & cancers owing to unhealthy lifestyle of people is the key driving factor for the market. Moreover, the growing geriatric population worldwide has also fuelling the demand of the market.
- High Expenditure on Healthcare Equipment’s due To Laboratory Automation
- Modern Clinical Laboratory Testing and Automation
- High Cost of the Product
- Lack of Skilled and Trained Professionals
- Risk of Outcome Ambiguity
- Advancements in Computer Technology and Real-Time Automation are Creating Lucrative Opportunities for the Market.
- Intense Competition in the Industry
Major Market Developments:
On January 16, 2019, Abbott, a leading healthcare company, has announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease.
On May 2, 2019, Beckman Coulter, a global leader in clinical diagnostics, announced that the latest addition to its market-leading automation portfolio, the DxA 5000 total laboratory automation solution has achieved European CE Mark and China Food and Drug Administration approval. The DxA 5000 supports laboratories in delivering highly consistent turnaround time to their physicians.
The Medical Device Amendments (MDA) of 1976 was passed to amend the FFDCA to “provide for the safety and effectiveness of medical devices”. The MDA includes an amendment to the FFDCA and the Federal Trade Commission Act to specifically define a “device” as any “instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease. Thus, in vitro reagents, as well as in vitro diagnostic products, when used for the diagnosis of disease are considered as medical devices under current federal regulations.
Clinical Laboratories and testing Centres, Hospitals and Clinics, Research Institutes and Organization and Industry Bodies and Association
Major Objectives Focused through this Study
To define, describe, and forecast the Global Clinical Chemistry Analyzer market on the basis of product [Low-Volume Chemistry Analyser, Automated Chemistry Analyser, Fully Automated Bench-top Analyser, Random Access Chemistry Analyser and Other] , application [Academic Research Institutes, Diagnostics Laboratories, Hospitals and Other], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Clinical Chemistry Analyzer market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Clinical Chemistry Analyzer industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Danaher Corporation (United States), DASA S.A (Brazil), Johnson & Johnson (United States), Labcompare (United States) and Hitachi (Japan).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Clinical Chemistry Analyzer market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.